Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Baseline disease modifying therapies (DMTs)----[1] 13 💬
2BG00012 (DMF)----[1] 13 💬
3BG00012 (DMF) (Tecfidera®.)----[1] 13 💬
4Biologic DMARD----[2] 46, 271 💬
5Biologic DMARDs----[1] 107 💬
6Biological DMARDs----[2] 86, 107 💬
7Classic DMARDs treatment group----[1] 46 💬
8Co-medication: Synthetic DMARDs----[1] 46 💬
9Combination of DMARDs----[1] 107 💬
10Conventional DMARD combination----[1] 46 💬
11Conventional DMARDs----[1] 46 💬
12Conventional Synthetic DMARD----[1] 46 💬
13CP-690-550-10 (DMID D1600180)----[1] 107 💬
14Daunorubicin
(DM)		[1] Daunorubicin[1] Daunorubicin (DM) 💬 [2] TOP2A,
TOP2B 💬 		[1] Platinum drug resistance 💬[1] 65 💬
15Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)[2] Dextromethorphan (Akin DM),
Quinidine		[2] Dextromethorphan ,
Quinidine 💬 		[11] GRIN1,
GRIN2A,
GRIN2B,
GRIN2C,
GRIN2D,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A,
SIGMAR1 💬 		[22] Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬[1] 8 💬
16Dimethyl Fumarate (DMF)[1] Dimethyl fumarate[1] Dimethyl fumarate 💬 [1] KEAP1 💬 [6] Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬[3] 13, 51, 86 💬
17Dimethyl fumarate [DMF][1] Dimethyl fumarate[1] Dimethyl fumarate 💬 [1] KEAP1 💬 [6] Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬[1] 13 💬
18Dimethyl sulfoxide (DMSO)[1] Dimethyl sulfoxide (DMSO)[1] Dimethyl sulfoxide 💬 --[1] 226 💬
19Disease modifying treatment (DMT)----[1] 13 💬
20Disease-modifying antirheumatic drugs (DMARDs)----[1] 46 💬
21DM----[2] 6, 8 💬
22DM-1992----[1] 6 💬
23DMARD----[1] 46 💬
24DMARD cessation----[1] 46 💬
25DMARD maintenance----[1] 46 💬
26DMARD Therapy----[1] 46 💬
27DMARDS----[2] 46, 271 💬
28DMARDs (disease-modifying antirheumatic drugs)----[1] 46 💬
29DMARDs (methotrexate[1] Methotrexate[1] Methotrexate 💬 [2] DHFR,
DHFR2 💬 		[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬[1] 46 💬
30DMARDs or Biologics----[1] 46 💬
31DMPS[1] 2,3-Dimercapto-1-propanesulfonic acid (DMPS)---[1] 171 💬
32DMSA[1] Succimer (DMSA)[1] Succimer 💬 --[1] 171 💬
33DMSO[1] Dimethyl sulfoxide (DMSO)[1] Dimethyl sulfoxide 💬 --[1] 226 💬
34DMSO cocktail[1] Dimethyl sulfoxide (DMSO)[1] Dimethyl sulfoxide 💬 --[1] 226 💬
35DMT----[1] 13 💬
36DMT continuation----[1] 13 💬
37DMX-200----[1] 222 💬
38Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc[1] Etanercept[1] Etanercept 💬 [2] LTA,
TNF 💬 		[67] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬[1] 46 💬
39Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS----[1] 13 💬
40First line DMT----[1] 13 💬
41HUC-MSC + DMARDs----[1] 46 💬
42Injectable MS DMT----[1] 13 💬
43IONIS-DMPKRx----[1] 113 💬
44Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)----[1] 46 💬
45Non-Biologic DMARDs----[3] 46, 86, 107 💬
46Non-biological DMARDs----[1] 46 💬
47Nonbiologic DMARDs of investigator's choice----[1] 46 💬
48Patient treated with DMARD----[1] 46 💬
49Permitted DMARDs----[1] 46 💬
50Phase 1: Conventiaonal DMARD----[1] 46 💬
51Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)----[1] 46 💬
52Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)----[1] 46 💬
53Standard MS DMT----[1] 13 💬
54Standard MS DMTs----[1] 13 💬
55Synthetic DMARD(s)----[1] 46 💬
56Targeted synthetic DMARD class----[1] 46 💬
57Therapy with disease-modifying anti rheumatic drugs (DMARD)----[1] 46 💬
58TNF-a antagonists, non-TNFs, DMARD non-biologics----[2] 46, 271 💬
59Trivalent chromium versus synthetic and/ or biological DMARDs[1] Chromium---[1] 46 💬
60UC-MSC+DMARDS----[1] 46 💬
61Vinblastine, vincristine, prednisone, daunorubicin
(DM)		[4] Daunorubicin,
Prednisone,
Vinblastine,
Vincristine		[4] Prednisone ,
Daunorubicin (DM),
Vinblastine ,
Vincristine 💬 		[12] NR3C1,
TOP2A,
TOP2B,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬 		[12] Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Platinum drug resistance, Prion disease, Salmonella infection 💬[1] 65 💬